Last reviewed · How we verify
NCT05675826
The Impact of Donor COVID-19 Infection Status on the Recipient in Allo-HSCT
trial in COVID-19 in 40 participants. Status unknown.
31 January 2023
Quick facts
| Lead sponsor | Chen Suning |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 26 December 2022 |
| Primary completion | 31 January 2023 |
| Estimated completion | 30 April 2023 |
| Sites | 1 location across China |
Conditions studied
- COVID-19 — all drugs for COVID-19 →
- Hematopoietic Stem Cell Transplantation — all drugs for Hematopoietic Stem Cell Transplantation →
Sponsor
Chen Suning — full company profile →
Who can join
Adults 16 to 65, any sex, with COVID-19 or Hematopoietic Stem Cell Transplantation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study was conducted to observe whether COVID-19 can be transmitted through stem cell transplantation and whether COVID-19-positive donors have an effect on early hematopoietic reconstitution and immune reconstitution in the recipients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05675826
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Chen Suning trials
Trials by the same sponsor.
- NCT06746519 — BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia · Phase 1, PHASE2 · recruiting
- NCT06250959 — RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL. · Phase 2 · recruiting
- NCT05466175 — A Study of Olverembatinib in the Treatment of Ph+ ALL · Phase 2 · unknown
- NCT05557110 — Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL · Phase 2 · completed
- NCT05177731 — Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML · Phase 3 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05675826 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chen Suning
- Last refreshed: 12 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05675826.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing